UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Patients may respond differently to paper and electronic versions of the same questionnaires

Respiratory medicine, 2009-06, Vol.103 (6), p.932-934

2009

Volltextzugriff (PDF)

CTNI-71. RELA FUSION-POSITIVE EPENDYMOMA, DIFFUSE MIDLINE GLIOMA AND GRADE 4 IDH MUTANT ASTROCYTOMA TREATED WITH VAL-083 UNDER EXPANDED ACCESS: CASE REPORTS

Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii113-viii113

2024

Volltextzugriff (PDF)

Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report

Glioma, 2019-01, Vol.2 (4), p.167-173

2019

Volltextzugriff (PDF)

DDDR-36. VAL-083 IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED UNDER EXPANDED ACCESS PROGRAM

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii107-vii107

2022

Volltextzugriff (PDF)

DDDR-34. RECURRENT RELA FUSION-POSITIVE EPENDYMOMA TREATED WITH VAL-083 UNDER EXPANDED ACCESS: A CASE REPORT

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii106-vii106

2022

Volltextzugriff (PDF)

CTNI-73. ASSESSMENT OF MOLECULAR ALTERATIONS IN NEWLY DIAGNOSED GBM MGMT-UNMETHYLATED PATIENTS TREATED WITH VAL-083

Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii114-viii114

2024

Volltextzugriff (PDF)

CTNI-72. VAL-083 IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED UNDER EXPANDED ACCESS PROGRAM

Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii113-viii114

2024

Volltextzugriff (PDF)

Abstract P081: In vitro activity and efficacy of novel dual PARP-HDAC inhibitors

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P081-P081

2021

Volltextzugriff (PDF)

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma

Clinical cancer research, 2023-09, Vol.29 (17), p.3541-3553

2023

Volltextzugriff (PDF)

DDDR-15. UTILIZING DEEP DOCKING AND ARTIFICIAL INTELLIGENCE FOR THE DISCOVERY OF NOVEL PARP1-SELECTIVE INHIBITORS FOR USE AGAINST BRAIN TUMORS

Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii128-viii129

2024

Volltextzugriff (PDF)

CTNI-78. EVALUATION OF POST-PROGRESSION TREATMENTS AFTER VAL-083 IN RECURRENT AND NEWLY DIAGNOSED GBM MGMT-UNMETHYLATED PATIENTS

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v95-v96

2023

Volltextzugriff (PDF)

CTNI-77. POST-PROGRESSION TREATMENT AFTER VAL-083 WITH RADIATION IN NEWLY DIAGNOSED GBM MGMT UNMETHYLATED PATIENTS

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v95-v95

2023

Volltextzugriff (PDF)

Abstract CT172: Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT172-CT172

2021

Volltextzugriff (PDF)

Abstract CT115: Phase II study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT115-CT115

2019

Volltextzugriff (PDF)

Abstract CT116: Phase I/II study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT116-CT116

2019

Volltextzugriff (PDF)

CTNI-26. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi65-vi65

2021

Volltextzugriff (PDF)

Abstract CT273: Phase 2 trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated glioblastoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT273-CT273

2020

Volltextzugriff (PDF)

CTNI-21. PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi63-vi64

2021

Volltextzugriff (PDF)

Abstract CT238: Phase 2 study of dianhydrogalactitol (VAL-083) inpatients with MGMT-unmethylated, bevacizumab-naivepatients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT238-CT238

2021

Volltextzugriff (PDF)

Abstract CT168: Phase I/II study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed glioblastoma, MGMT-unmethylated

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT168-CT168

2018

Volltextzugriff (PDF)

Abstract LB126: RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB126-LB126

2023

Volltextzugriff (PDF)

CTNI-72. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii59-ii59

2020

Volltextzugriff (PDF)

Abstract CT272: Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent or adjuvant setting

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT272-CT272

2020

Volltextzugriff (PDF)

CTNI-76. PHASE 2 CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii60-ii60

2020

Volltextzugriff (PDF)

ACTR-27. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE RECURRENT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi17-vi17

2018

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(82)

Publikationsform

Sprache

Englisch
(88)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Humans
(24)
Biological And Medical Sciences
(18)
Female
(15)
Medical Sciences
(14)
Middle Aged
(13)
Adult
(11)
Male
(10)
Oncology
(9)
Aged
(8)
Animals
(8)
Treatment Outcome
(8)
Combined Modality Therapy
(7)
Surgery
(7)
Breast Neoplasms - Radiotherapy
(6)
Mastectomy
(6)
Prospective Studies
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Breast Neoplasms - Pathology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Patients may respond differently to paper and electronic versions of the same questionnaires

CTNI-71. RELA FUSION-POSITIVE EPENDYMOMA, DIFFUSE MIDLINE GLIOMA AND GRADE 4 IDH MUTANT ASTROCYTOMA TREATED WITH VAL-083 UNDER EXPANDED ACCESS: CASE REPORTS

Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report

DDDR-36. VAL-083 IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED UNDER EXPANDED ACCESS PROGRAM

DDDR-34. RECURRENT RELA FUSION-POSITIVE EPENDYMOMA TREATED WITH VAL-083 UNDER EXPANDED ACCESS: A CASE REPORT

CTNI-73. ASSESSMENT OF MOLECULAR ALTERATIONS IN NEWLY DIAGNOSED GBM MGMT-UNMETHYLATED PATIENTS TREATED WITH VAL-083

CTNI-72. VAL-083 IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED UNDER EXPANDED ACCESS PROGRAM

Abstract P081: In vitro activity and efficacy of novel dual PARP-HDAC inhibitors

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma

DDDR-15. UTILIZING DEEP DOCKING AND ARTIFICIAL INTELLIGENCE FOR THE DISCOVERY OF NOVEL PARP1-SELECTIVE INHIBITORS FOR USE AGAINST BRAIN TUMORS

CTNI-78. EVALUATION OF POST-PROGRESSION TREATMENTS AFTER VAL-083 IN RECURRENT AND NEWLY DIAGNOSED GBM MGMT-UNMETHYLATED PATIENTS

CTNI-77. POST-PROGRESSION TREATMENT AFTER VAL-083 WITH RADIATION IN NEWLY DIAGNOSED GBM MGMT UNMETHYLATED PATIENTS

Abstract CT172: Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM

Abstract CT115: Phase II study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma

Abstract CT116: Phase I/II study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma

CTNI-26. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

Abstract CT273: Phase 2 trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated glioblastoma

CTNI-21. PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM

Abstract CT238: Phase 2 study of dianhydrogalactitol (VAL-083) inpatients with MGMT-unmethylated, bevacizumab-naivepatients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting

Abstract CT168: Phase I/II study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed glioblastoma, MGMT-unmethylated

Abstract LB126: RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports

CTNI-72. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

Abstract CT272: Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent or adjuvant setting

CTNI-76. PHASE 2 CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM

ACTR-27. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE RECURRENT GLIOBLASTOMA

Suchergebnisse filtern